Frontlight ResearchEarly access
CompletedPhase 2
A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant Dermatomyositis
Key facts
- Who runs it
- Priovant Therapeutics, Inc.
- Where
- Scottsdale, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 5 people enrolled
- Started
- 28 Aug 2024
- Ended
- 28 Feb 2025
- Type of study
- Interventional
- Treatments tested
- Brepocitinib
- Record updated
- 20 May 2025
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- A diagnosis of dermatomyositis according to 2017 EULAR/ACR Classification Criteria for Idiopathic Inflammatory Myopathies
- Active cutaneous manifestations of dermatomyositis
- Adult subjects (18-75 years old)
- Weight > 40 kg to < 130 kg, and with a body mass index (BMI) < 40 kg/m2
Who cannot take part
- Dermatomyositis with irreversible muscle involvement; History of:
- Any lymphoproliferative disorder
- Active malignancy
- History of cancer within 5 years prior to randomization (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid carcinoma.) Cancer-associated dermatomyositis
- Overlap myositis/connective tissue disease (except for overlap with Sjögren's syndrome)
- Participants at a risk of thrombosis or cardiovascular disease
- Participants with active or recent infections
- Dermatomyositis with end-stage organ involvement
- Participants with a high risk for herpes zoster reactivation
Where in United States
- Scottsdale, ArizonaHospital not named in the registry
About the trial
What the trial wants to find out
This is a prospective, 12-week, open-label, single-arm study. The study population comprises individuals with refractory skin disease characteristic of dermatomyositis with no to minimal muscle involvement. After an up to 8-week Screening Period, eligible participants will receive brepocitinib 30 mg orally (PO) QD for 12 weeks.
The group in the trial
- BrepocitinibTreatment being tested
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A 12-Week Open-Label Pilot Study to Investigate the Efficacy and Safety of Oral Brepocitinib in Adults With Skin-Predominant Dermatomyositis
- Record updated
- 20 May 2025